Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 335
- Registration Number
- NCT02243202
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT02243189
Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02231489
Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 382
- Registration Number
- NCT02230059
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 102
- Registration Number
- NCT02230046
Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02228239
Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults
Early Phase 1
Completed
- Conditions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02221726
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT02221180
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT02220218
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02217566
© Copyright 2024. All Rights Reserved by MedPath